美托洛尔治疗不伴心力衰竭的扩张型心肌病的疗效观察

目的探讨美托洛尔治疗不伴有心力衰竭的扩张型心肌病的临床疗效。方法将湖南省桃源县红十字会医院收治的94例早期扩张型心肌病患者随机分为观察组和对照组,各47例。均给予吸氧、抗凝、抗血小板聚集、强心、利尿,扩血管及降低心脏负荷等常规治疗和对症处理。观察组患者在此基础上加用美托洛尔口服治疗。所有患者均接受6个月的治疗,测定患者治疗前后左房内径(LA)、左室舒张末期内径(LVEDD)和左室射血分数(LVEF),并评估两组患者接受治疗后的生活质量。结果两组患者接受治疗后心率、左房内径、左室舒张末期内径和左室射血分数均显著优于治疗前,差异有统计学意义(P<0.05),且观察组显著优于对照组,差异有统计学意义(P<0.05);所有患者接受治疗6个月后,观察组患者生活质量总分显著高于对照组患者(P<0.01)。结论美托洛尔治疗不伴有心力衰竭的扩张型心肌病患者可显著改善各项心功能指标,延缓疾病发展,提高患者生活质量,值得临床推广。

Objective To research the effect of metoprolol in treating DCM without heart failure. Methods Divided 94 patients with metoprolol in treating dilated cardiomyopathy without heart failure into 2 groups. Every patient was given regular treatment including oxygen Inhalation, anticoagulation,diuresis and heart strengthen. The 47 patients in observation group were given metoprolol on the basis of regular treatment. Results The levels of HR, LA, LVEDD and LVEF of the two groups were all superior to those before treatment（P0.05） while the levels ub observation group were superior to those in control group （P0.05）. The score of living quality after treatment in observation group was higher than control group（P0.01）. Conclusion The clinical effect of metoprolol is remarkable in treating DCM without HF.